The role of low-density lipoprotein cholesterol (LDL-C) in the evolution of heart disease is fairly well established. In addition, the benefits of pharmacological treatment with agents that lower LDL-C in high-risk patients are well documented. Lipoproteins are biochemical structures that enable the transport of lipids such as cholesterol in the circulation. LDL-C represents the amount … Read more
The death rate from coronary artery disease (CAD) has declined considerably over the last three decades. This is mainly due to better control of risk factors and advances in therapy. However, the prevalence of CAD remains high due to the aging of the population and better survival of those affected. The current epidemic of obesity … Read more
The results of the recently completed FOURIER trial suggest that we have taken a huge step forward in the pharmacological therapy atherosclerotic cardiovascular disease (ASCVD). On February 2, 2017 the biotechnological company Amgen announced that the FOURIER trial evaluating whether the drug evolocumab (Repatha) reduces the risk of cardiovascular events in patients with clinically evident ASCVD … Read more
Knowing the role of VLDL (very low-density lipoprotein) and chylomicrons is a key factor in understanding how lipids (fats) and lipoproteins are involved in atherosclerotic cardiovascular disease (ASCVD). In the current era of adiposity and metabolic disease, VLDL has gained a bigger role than before and may help explain many of the disorders associated with the obesity epidemic such … Read more
Data presented at the World Heart Federation’s World Congress of Cardiology & Cardiovascular Health 2016 (WCC 2016) in Mexico City may radically change our perspective on how carbohydrates and different types of fats affect blood cholesterol and other lipid biomarkers. The presentation was based on data from the Prospective Urban Rural Epidemiological (PURE) study. The data have not been … Read more